Clinical Trials Logo

Filter by:
NCT ID: NCT03372057 Completed - Clinical trials for Peripheral T-cell Lymphoma

A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

PRIMO
Start date: February 22, 2018
Phase: Phase 2
Study type: Interventional

This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed/refractory Peripheral T-cell Lymphoma (PTCL).

NCT ID: NCT03371810 Completed - Obesity Clinical Trials

Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder

PROUD
Start date: March 13, 2017
Phase: Phase 2
Study type: Interventional

Depression and obesity are very common among adolescents and young adults with attention-deficit/ hyperactivity disorder (ADHD). However, intervention programmes to prevent these comorbid disorders rarely exist. In a pilot randomized-controlled study we test two newly developed intervention programmes that do not involve medication: bright light therapy and physical exercise. Both interventions will be supported by a mobile Health application to monitor and feedback intervention success and booster patients' motivation.

NCT ID: NCT03371485 Completed - Clinical trials for Advanced Non-small Cell Lung Cancer

AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer

Start date: June 1, 2018
Phase: Phase 1
Study type: Interventional

This clinical study is looking at a vaccine called AST-VAC2 in adult patients with advanced non-small cell lung cancer (NSCLC). The main aim of the study: If the dose can be given safely to patients, learn more about the potential side effects of the vaccine and how they can be managed and also what happens to AST-VAC2 inside the body (looking for effects in the blood, skin or tumour).

NCT ID: NCT03370822 Completed - Fetal Distress Clinical Trials

A Mixed Methods Study to Explore the Feasibility of a Novel Continuous Fetal Monitoring Device

Start date: June 22, 2016
Phase:
Study type: Observational

A stillbirth describes when a baby dies after 24 weeks of pregnancy and before being born. In the UK there are roughly 9 stillbirths every day. Normally, before a stillbirth occurs changes such as a slower heart rate and reduced movement take place. Fetal monitoring attempts to detect these changes so that babies can be delivered before they become severely ill. If a baby could be monitored continuously then these changes could be detected earlier. However, current forms of fetal monitoring, such as ultrasound, cannot be used for long periods of time and do not significantly reduce stillbirth rates. The Monica AN24 device is a continuous monitor which records the baby's heart rhythm using sensors placed on the mother's abdomen. As this is a new device there is little evidence about how well it works. In this project women will be asked how they feel about the device after wearing it. Doctors and midwives will also be asked about their views of the device. The effect of the mother's movement and the age of the baby on how well the Monica AN24 can record the baby's heart rhythm will also be assessed.

NCT ID: NCT03370653 Completed - Clinical trials for Mucopolysaccharidosis VI

A Study in MPS VI to Assess Safety and Efficacy of Odiparcil

iMProveS
Start date: December 30, 2017
Phase: Phase 2
Study type: Interventional

Mucopolysaccharidoses (MPS) are a group of rare inherited disorders characterized by a deficiency of lysosomal enzymes responsible for the normal degradation of glycosaminoglycans (GAGs). Medical need for treatment of MPS is still very high due to the poor penetration of the recombinant enzymes into the blood brain barrier as well as the ocular barriers and into tissues that are poorly vascularized, such as cartilages and bones. Odiparcil is an orally active compound that allows the synthesis of soluble glycosaminoglycans (GAGs), mainly chondroitin sulfate (CS) and dermatane sulfate (DS). The neosynthesized solubles GAGs are then excreted in urine. By diverting endogenous GAG synthesis to the synthesis of soluble odiparcil linked GAGs, odiparcil should decrease the intracellular pool of GAGs and consequently decrease the lysosomal GAG accumulation. The primary objective of the study is to assess the safety and efficacy of two doses of odiparcil in MPS VI patients and to provide evidence to enable the selection of the relevant dose of odiparcil for phase III study. The secondary objective of this study is to characterize the dose response, PK and PD of odiparcil.

NCT ID: NCT03370497 Completed - Obesity Clinical Trials

Calcium-protein Co-ingestion and Gut Hormones

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

Gut hormones have therapeutic potential in the prevention and treatment obesity and type 2 diabetes (T2D). Rodent evidence suggests that calcium may potentiate the effects of protein ingestion on gut hormone secretion. Evidence in humans however, is lacking. This study aims to assess whether the addition of calcium to protein ingestion augments postprandial gut hormone availability in humans.

NCT ID: NCT03370484 Completed - Obesity Clinical Trials

Calcium and Gut Hormones

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

Gut hormones have therapeutic potential in the prevention and treatment obesity and type 2 diabetes (T2D). Rodent evidence suggests that calcium may stimulate gut hormone secretion. Evidence in humans however, is lacking. This study aims to assess whether the calcium ingestion stimulates gut hormone availability in humans.

NCT ID: NCT03370133 Completed - Psoriatic Arthritis Clinical Trials

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

BE VIVID
Start date: December 6, 2017
Phase: Phase 3
Study type: Interventional

This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).

NCT ID: NCT03369665 Completed - Multiple Sclerosis Clinical Trials

Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)

Start date: June 20, 2018
Phase: Phase 4
Study type: Interventional

The main purpose of the study was to assess the health-related quality of life (HRQoL) through the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active relapsing multiple sclerosis (RMS) particpants treated with Mavenclad® for 2 years (24 months).

NCT ID: NCT03369431 Completed - Clinical trials for Autism Spectrum Disorder

Efficacy of Vivomixx on Behaviour and Gut Function in Autism Spectrum Disorder

VIVO-ASD
Start date: February 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effects of 3 months supplementation with the multi strain probiotic Vivomixx on the overall function, aberrant behaviours and frequency of gastrointestinal symptoms in children with Autism Spectrum Disorders and co-morbid gastrointestinal symptoms. The investigators will also assess the effect of the intervention on parenting stress. A further issue will be to identify any predictors of response to the probiotic. Finally, the investigators will assess whether there is an association between altered behaviour and altered gut function in users of Vivomixx.